Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Dr Martin Kolb: Addressing IPF Mortality and Costs Through Timely Intervention
Early intervention for idiopathic pulmonary fibrosis (IPF) is crucial due to the high mortality rate, with emerging therapies like nerandomilast showing potential to reduce health care costs by preventing disease progression.
Surgery Improves Outcomes for Patients With Atrial Functional Mitral Regurgitation
A new study found that older patients with atrial functional mitral regurgitation who underwent mitral valve surgery had significantly better outcomes than those who received medical management alone, including lower rates of heart failure hospitalization and death.
In ASPC President’s Address, Dr Martha Gulati Reflects on Progress and Future Goals in Cardiology
Martha Gulati, MD, MS, discusses the accomplishments of the American Society of Preventive Cardiology (ASPC) during her presidency and emphasizes the importance of advancing preventive cardiology.
FDA Approval of Epcoritamab Offers New Hope for R/R Follicular Lymphoma Treatment
“It's nice to have another option that we can discuss with patients,” said Yasmin H. Karimi, MD, University of Michigan, about epcoritamab’s label expansion for difficult-to-treat relapsed/refractory (R/R) follicular lymphoma.
Patient Response to Pirfenidone, Nintedanib for IPF Differs in Real World vs Trials
While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world settings.
Dr Paul Frohna Details Plans for Further Research on ENV-101 for IPF
The ENV-101 phase 2a trial for idiopathic pulmonary fibrosis (IPF) focused on assessing safety, lung function, and fibrosis, with plans for further trials, combination therapies, and strategies to manage adverse effects.